Effect of Proton Pump Inhibitors on the Management of GERD in the Department of Gastroenterology HMC Peshawar

Background: In this trial, patients treated at the Department of Gastroenterology, Hayatabad Medical Complex in Peshawar, would have their gastroesophageal reflux disease (GERD) managed with proton pump inhibitor (PPI) medication. The treatment of omeprazole (40 mg once daily) or famotidine (40 mg O.D. daily) for 12 months was randomly allocated to 100 patients with GERD. The primary outcome measure was the mean change in oesophageal acid exposure time from baseline to twelve months. The frequency of GERD-related symptoms and general health-related quality of life over time were considered secondary objectives. Endoscopic results were also documented at the beginning and after a year. The study's adverse occurrences were kept under observation. The findings demonstrated that from baseline to twelve months, the mean oesophageal acid exposure duration significantly decreased in both PPI groups (mean S.E., 18.9 1.7 minutes for omeprazole group against 16.4 2.1 minutes for famotidine group, p0.001). Additionally, the treatment groups substantially outperformed the control groups at twelve months compared to baseline regarding the mean Frequency of GERD-related symptoms and overall health-related quality of life (p 0.001). There were no documented severe adverse events. GERD may be effectively and safely treated with PPI medication, and there are no clinically significant differences between omeprazole and famotidine.